Ng Kelvin Kwok Lap, Rozen Genia, Stewart Tanya, Agresta Franca, Polyakov Alex
Royal Melbourne Hospital.
Royal Women's Hospital, Parkville.
Medicine (Baltimore). 2019 Jan;98(4):e14251. doi: 10.1097/MD.0000000000014251.
Implantation failure is the main factor affecting the success rate of in vitro fertilization (IVF) procedures. Studies have reported that uterine contractions (UC) at the time of embryo transfer (ET) were inversely related to implantation and pregnancy rate, hence reducing the success of IVF treatments. Various pharmacological agents, with the exception of calcium channel blockers, have been investigated to improve ET outcomes by reducing UC. Thus, a double-blinded randomized, placebo-controlled trial was conducted to determine whether nifedipine, a calcium channel blocker with potent smooth muscle relaxing activity and an excellent safety profile, can improve the outcome of patients undergoing ET treatments.
Ninety-three infertile women were recruited into 1 of 2 groups: placebo (n = 47) or nifedipine 20 mg (n = 46). Study participants were admitted 30 minutes prior to ET and given either tablet after their baseline vital signs were recorded. They then underwent ET and were observed for adverse events for another 30 minutes post-ET. Follow up of the participants' outcomes was conducted via electronic medical records. The primary outcomes are implantation and clinical pregnancy rates. Secondary outcomes include any maternal or fetal adverse events, miscarriage, pregnancy, live births, and neonatal outcomes. Resulting data were then analyzed using t test, Pearson chi-square test, and Fisher exact test to compare outcomes between the 2 groups.
No statistical differences in the implantation rate (42.6% vs 39.1%, P = .737, rate ratio 0.868, 95% confidence interval [CI]: 0.379-1.986) and the clinical pregnancy rate (23.4% vs 26.1%, P = .764, rate ratio 1.155, 95% CI: 0.450-2.966) were detected between the placebo and the treatment groups. In addition, no statistical significance between the placebo and the treatment groups for any secondary outcomes were detected.
This double blinded, randomized, and placebo-controlled trial demonstrated that the single use of 20 mg nifedipine given 30 minutes before embryo transfer did not improve the implantation rate or the clinical pregnancy rate of the infertility treatment. Further studies are required to demonstrate the clinical benefits and risks of nifedipine usage in embryo transfer.
着床失败是影响体外受精(IVF)成功率的主要因素。研究报告称,胚胎移植(ET)时的子宫收缩(UC)与着床率和妊娠率呈负相关,从而降低了IVF治疗的成功率。除钙通道阻滞剂外,已对各种药物进行了研究,以通过减少子宫收缩来改善胚胎移植结局。因此,进行了一项双盲随机、安慰剂对照试验,以确定硝苯地平(一种具有强大平滑肌舒张活性且安全性良好的钙通道阻滞剂)是否能改善接受胚胎移植治疗患者的结局。
93名不孕妇女被分为两组中的一组:安慰剂组(n = 47)或硝苯地平20mg组(n = 46)。研究参与者在胚胎移植前30分钟入院,在记录其基线生命体征后给予相应片剂。然后他们接受胚胎移植,并在移植后再观察30分钟以记录不良事件。通过电子病历对参与者的结局进行随访。主要结局是着床率和临床妊娠率。次要结局包括任何母体或胎儿不良事件、流产、妊娠、活产和新生儿结局。然后使用t检验、Pearson卡方检验和Fisher精确检验分析所得数据,以比较两组之间的结局。
安慰剂组和治疗组之间在着床率(42.6%对39.1%,P = 0.737,率比0.868,95%置信区间[CI]:0.379 - 1.986)和临床妊娠率(23.4%对26.1%,P = 0.764,率比1.155,95%CI:0.450 - 2.966)方面未检测到统计学差异。此外,在安慰剂组和治疗组之间的任何次要结局方面均未检测到统计学显著性。
这项双盲、随机、安慰剂对照试验表明,在胚胎移植前30分钟单次使用20mg硝苯地平并不能提高不孕治疗的着床率或临床妊娠率。需要进一步研究以证明硝苯地平在胚胎移植中使用的临床益处和风险。